Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatients practice

Arthritis and Rheumatism

Volumn 40, Issue 8, 1997, Pages 1482-1486

  Levy, G D ^a,c   Munz, S J ^a   Paschal, J ^a   Cohen, H B ^b   Pince, K J ^a   Peterson, T ^b  

^a KAISER PERMANENTE   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE;

AGED; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OPHTHALMOLOGY; PRIORITY JOURNAL; RETINOPATHY; SCREENING;

ADULT; AGED; ANTIMALARIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYCHLOROQUINE; INCIDENCE; MALE; MIDDLE AGED; MULTICENTER STUDIES; RETINAL DISEASES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0030954774     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400817     Document Type: Article

References (20)

1. Cambiaggi A: Unusual ocular lesions in a case of systemic lupus erythematosus. Arch Ophthalmol 57:451-457, 1957
2. Hobbs HE, Sorsby A, Freedman A: Retinopathy following chloroquine therapy. Lancet 2:478-480, 1959
3. Bernstein HN: Chloroquine ocular toxicity. Surv Ophthalmol 12:415-443, 1967
4. Finbloom DS, Silver K, Newsome DA, Gunkel R: Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 12:692-694, 1985
5. Raines MF, Bhargava SK, Rosen ES: The blood-retinal barrier in chloroquine retinopathy. Invest Ophthalmol Vis Sci 30:1726-1731, 1989
6. Bernstein HN: Ocular safety of hydroxychloroquine sulfate (Plaquenil). South Med J 85:274-279, 1992
7. Tobin DR, Krohel GB, Rynes RI: Hydroxychloroquine: seven-year experience. Arch Ophthalmol 100:81-83, 1982
8. Mackenzie AH: Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 75:40-45, 1983
9. Easterbrook M: The ocular safety of hydroxychloroquine. Semin Arthritis Rheum 23 (suppl 1):62-67, 1993
10. Spalton DJ, Verdon Roe GM, Hughes GRV: Hydroxychloroquine, dosage parameters and retinopathy. Lupus 2:355-358, 1993
11. Wallace DJ: Antimalarial agents and lupus. Rheum Dis Clin North Am 20:243-263, 1994
12. Morsman CDG, Livesey SJ, Richards IM, Jessop JD, Mills PV: Screening for hydroxychloroquine retinal toxicity: is it necessary? Eye 4:572-576, 1990
13. Morand EF, McCloud PI, Littlejohn GO: Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 51:1318-1321, 1992
14. Weise EE, Yannuzzi LA: Ring maculopathies mimicking chloroquine retinopathy. Am J Opthalmol 78:204-210, 1974
15. Mazzuca SA, Yung R, Brandt KD, Yee RD, Katz BP: Current practices for monitoring ocular toxicity related to hydroxychloroquine (Plaquenil) therapy. J Rheumatol 21:59-63, 1994
16. Johnson MW, Vine AK: Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol 104:139-144, 1987
17. Shearer R, Dubois E: Ocular changes induced by long-term hydroxychloroquine (Plaquenil) therapy. Am J Ophthalmol 64: 245-252, 1967
18. Rynes RI: Ophthalmologic safety of long term hydroxychloroquine sulfate treatment. Am J Med 75:35-39, 1983
19. The Canadian Hydroxychloroquine Study Group: A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324:150-154, 1991
20. MacLean CH, Lee PP, Keeler EB: Cost analysis of routine ophthalmologic screening for hydroxychloroquine retinal toxicity (abstract). Arthritis Rheum 39 (suppl 9):S72, 1996